Protocol M23-716: A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 12-63 years of age - have more than 50% hair loss

Exclusion Criteria:

- pregnancy

Conditions & Interventions

Conditions:
Dermatology (Skin, Hair & Nails)
Keywords:
Alopecia Areata

More Information

Description: This study will assess how effective and safe the use of the medication named Upadacitinib is for the treatment of signs and symptoms of severe hair loss in adults.
Study Contact: Dermatology Study - dermresearch@umn.edu
Principal Investigator: Maria Hordinsky
IRB Number: STUDY00021415